


9-11-06

IFW\$



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/680,449
Filing Date	October 6, 2003
First Named Inventor	Huang
Art Unit	1635
Examiner Name	L.V. Wollenberger
Attorney Docket Number	1438.01

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): -Copies of listed documents 28 documents
Remarks		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Company Name	Myriad Genetics, Inc.		
Signature			
Printed name	Herbert L. Ley III, Ph.D.		
Date	Sept. 8, 2006	Reg. No.	53,215

CERTIFICATE OF EXPRESS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated below and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Express Mail Label No. EV 600562016 US

Typed or printed name	Kerj Morris		
Signature		Date	September 8, 2006



Attorney Docket No. 1438.0.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Huang, et al.)

Application No.: 10/680,449)

Filed: October 6, 2003)

For: RNA INTERFERENCE USING A)
UNIVERSAL TARGET)

Group Art Unit: 1635

Examiner: L.V. Wollenberger

CERTIFICATE OF EXPRESS MAIL

"Express Mail" mailing label number: EV 600562016 US

Date of Deposit: September 8, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated below and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ker Morris
Ker Morris

September 8, 2006
Date

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97(c)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a list of documents on form PTO/SB/08A together with copies of each identified document. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicants are in no way making any admission as to prior art status of the listed documents, but are instead submitting the listed documents for the sake of full disclosure under 37 CFR § 1.56. Applicants have used best effort in providing a publication date for each document. However, discrepancies may occur due to online publishing and other publishing practices.

09/12/2006 RMEBRAFT 00000017 501627 10680449


01 FC:1806 180.00 DA

To the best of the undersigned person's knowledge, this Supplemental Information Disclosure Statement is being submitted in accordance with 37 CFR § 1.97(c), before either (a) the mailing date of a Final Office Action, (b) a Notice of Allowance, or (c) any other action that otherwise closes prosecution, whichever is earlier.

To comply with 37 § CFR 1.97(c)(2), please charge the fee of **\$180.00** under 37 CFR 1.17(p) to Deposit Account No. **50-1627**.

It is believed that neither an extension of time, nor payment of any other fee is required in connection with this communication. However, if an extension of time, a corresponding extension fee, or any other fee is required, such an extension of time is hereby petitioned for and the Commissioner is authorized to charge any fees, or credit any overpayment, to Deposit Account No. **50-1627**.

Respectfully submitted,


A handwritten signature in black ink, appearing to read 'Herbert L. Ley III', with a long horizontal flourish extending to the right.

Herbert L. Ley III, Ph.D.
Registration No. 53,215

Intellectual Property Department
Myriad Genetics, Inc.
(Customer No. 26698)
320 Wakara Way
Salt Lake City, UT 84108
Telephone: 801-584-3600
Fax: 801-883-3871

Date: September 8, 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.



Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/680,449
Filing Date	October 6, 2003
First Named Inventor	Huang
Art Unit	1635
Examiner Name	L.V. Wollenberger
Attorney Docket Number	1438.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BRUMMELKAMP et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells", <i>Science</i> , April 19, 2002, 296:550-553.	
		CAMPBELL et al., "Knockdown of chimeric glucocerebrosidase by green fluorescent protein-directed small interfering RNA", <i>Genetics and Molecular Research</i> , June 14, 2004, 3(2):282-287.	
		CAPLEN et al., "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems", <i>Proc. Natl. Acad. Sci. USA</i> , August 14, 2001, 98(17):9742-9747.	
		CAPLEN et al., "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems", <i>Proc. Natl. Acad. Sci. USA</i> , August 14, 2001, 98(14):9742-9747, Supplementary Material, Table 2. Sequences of RNA oligonucleotides, 1 page.	
		CASTANOTTO et al., "Functional siRNA expression from transfected PCR products", <i>RNA Journal</i> , 2002, 8:1454-1460.	
		CHIU et al., "RNAi in Human Cells: Basic Structural and Functional Features of Small Interfering RNA", <i>Molecular Cell</i> , September 2002, 10:549-561.	
		CHIU et al., "RNAi in Human Cells: Basic Structural and Functional Features of Small Interfering RNA", <i>Molecular Cell</i> , September 2002, 10:549-561. Supplemental Data: Description, Figure S1, Figure S2, 3 pages.	
		DOENCH et al., "siRNAs can function as miRNAs", <i>Genes & Development</i> , 2003, 17:438-442.	
		DONZE et al., "RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase", <i>Nucleic Acids Research</i> , 2002, 30(10):46:1-4.	
		ELBASHIR et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs", <i>Methods</i> , 2002, 26:199-213.	
		ELBASHIR et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", <i>Nature</i> , May 24, 2001, 411:494-498.	
		ELBASHIR et al., "Functional anatomy of siRNAs for mediating efficient RNAi in <i>Drosophila melanogaster</i> embryo lysate", <i>The EMBO Journal</i> , December 3, 2001, 20(23):6877-6888.	
		HOLEN et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor" <i>Nucleic Acids Research</i> , April 2002, 30(8):1757-1766.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/680,449	
			Filing Date	October 6, 2003	
			First Named Inventor	Huang	
			Art Unit	1635	
			Examiner Name	L.V. Wollenberger	
Sheet	2	of	3	Attorney Docket Number	1438.01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LEE et al., "Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells", <i>Nature Biotechnology</i> , May 2002, 19:500-505.	
		LEIRDAL et al., "Gene silencing in mammalian cells by preformed small RNA duplexes", <i>Biochemical and Biophysical Research Communications</i> , 2002, 295:744-748.	
		MARTINEZ et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi", <i>Cell</i> , September 6, 2002, 110:563-574.	
		MIYAGISHI et al., "U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells", <i>Nature Biotechnology</i> , May 2002, 20:497-500.	
		NAGY et al., "Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells", <i>Exp Cell Res.</i> , April 15, 2003, 285(1):39-49.	
		PARRISH et al., "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference", <i>Molecular Cell</i> , November 2000, 6:1077-1087.	
		PADDISON et al., "Short hairpin RNA's (shRNAs) induce sequence-specific silencing in mammalian cells", <i>Genes & Development</i> , April 15, 2002, 16(8):948-958.	
		PAUL et al., "Effective expression of small interfering RNA in human cells", <i>Nature Biotechnology</i> , May 2002, 20:505-508.	
		RUBINSON et al., "A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference", <i>Nature Genetics</i> , March 2003, 33:401-406.	
		SEMIZAROV et al., "Specificity of short interfering RNA determined through gene expression signatures", <i>Proc. Natl. Acad. Sci. USA</i> , May 27, 2003, 100(11):6347-6352.	
		SUI et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells", <i>Proc. Natl. Acad. Sci. USA</i> , April 16, 2002, 99(8):5515-5520.	
		TISCORNIA et al., "A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA", <i>Proc. Natl. Acad. Sci. USA</i> , February 18, 2003, 100(4):1844-1848.	
		XIA et al., "siRNA-mediated gene silencing in vitro and in vivo", <i>Nature Biotechnology</i> , October 2002, 20:1006-1010.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/680,449
				Filing Date	October 6, 2003
				First Named Inventor	Huang
				Art Unit	1635
				Examiner Name	L.V. Wollenberger
				Attorney Docket Number	1438.01
Sheet	3	of	3		

[illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.